Zydus Lifesciences Limited has reported a strong financial performance for the quarter and year ended March 31, 2026. The company achieved a 16% year-over-year revenue growth in Q4, reaching Rs. 75,870 million. With an EBITDA margin of 33.7% and a net profit of Rs. 15,929 million, the company continues to demonstrate robust operational momentum across its key business segments, including India formulations, North America, and Consumer Wellness.
Robust Operational Growth
For the fiscal year 2026, Zydus Lifesciences posted total revenues of Rs. 2,71,484 million, reflecting a 16.8% increase compared to the previous year. The Q4 performance was particularly strong, with EBITDA growing by 20% year-over-year to Rs. 25,544 million. This growth was driven by sustained momentum in India’s branded formulations business and expanded volume in the North American market.
Strategic Business Highlights
The company’s India formulations business outpaced market growth with a 15% year-over-year increase, bolstered by a strong chronic portfolio which now accounts for 46.3% of its sales. In the North American market, the company solidified its position as the 3rd largest generic company by prescription volume. Meanwhile, the Consumer Wellness division saw a significant performance boost, recording 61.1% year-over-year growth in Q4, supported by the integration of the CCL business.
Innovation and Shareholder Value
Innovation remains a core driver, with Rs. 6,982 million invested in R&D during the quarter. Key milestones include the launch of the world’s first biosimilar of Nivolumab and continued progress in NCE and biotech research. Additionally, in a move to reward shareholders, the Board of Directors has approved a buy-back of shares valued at up to Rs. 11,000 million at a price of Rs. 1,150 per share.
ESG Commitments
Zydus continues to make strides in sustainability, achieving an S&P Global ESG score of 84. The company remains committed to its net carbon neutral goal by 2035 and has already achieved 74% of its renewable energy target for FY2026, demonstrating a balanced approach to financial and environmental stewardship.
Source: BSE
